Etanercept

This article examines the use of etanercept (Enbrel) in clinical trials for several conditions including ankylosing spondylitis, rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and plaque psoriasis. Etanercept is a biologic medication that works by reducing inflammation in the body. The trials assess its efficacy, safety, optimal dosing, and potential for discontinuation after achieving remission. Key measures include disease activity scores, patient-reported outcomes, and radiographic progression.

Table of Contents

What is Etanercept?

Etanercept, also known by the brand name Enbrel, is a biologic drug used to treat various inflammatory conditions[1]. It belongs to a class of medications called tumor necrosis factor (TNF) inhibitors. Etanercept works by reducing inflammation in the body, which helps alleviate symptoms and slow down disease progression in certain autoimmune disorders[1].

What Conditions Does Etanercept Treat?

Etanercept is approved to treat several inflammatory conditions, including:

  • Rheumatoid Arthritis (RA): A chronic inflammatory disorder that affects the joints, causing pain, stiffness, and swelling[1]
  • Psoriatic Arthritis (PsA): A form of arthritis that affects some people with psoriasis, causing joint pain, stiffness, and swelling[1]
  • Ankylosing Spondylitis (AS): A type of arthritis that primarily affects the spine, causing back pain and stiffness[5]
  • Plaque Psoriasis: A skin condition characterized by red, scaly patches on the skin[6]
  • Juvenile Idiopathic Arthritis (JIA): A form of arthritis that affects children and teenagers[7]

How Does Etanercept Work?

Etanercept works by targeting and blocking a protein called tumor necrosis factor-alpha (TNF-alpha). TNF-alpha is a key player in the body’s inflammatory response. In people with autoimmune conditions, there is often an overproduction of TNF-alpha, leading to excessive inflammation and tissue damage. By blocking TNF-alpha, etanercept helps reduce inflammation and alleviate symptoms associated with these conditions[1].

How is Etanercept Administered?

Etanercept is typically administered as a subcutaneous injection (an injection under the skin). The usual dosage for adults is 50 mg once a week or 25 mg twice a week[5]. For children, the dosage is based on their weight. The medication can be self-administered at home after proper training from a healthcare professional[7].

Effectiveness of Etanercept

Clinical trials have shown etanercept to be effective in treating various inflammatory conditions:

  • In rheumatoid arthritis, etanercept has been shown to reduce disease activity and improve physical function[8]
  • For psoriatic arthritis, etanercept can improve both joint symptoms and skin lesions[4]
  • In ankylosing spondylitis, etanercept has been effective in reducing back pain and improving overall function[5]
  • For plaque psoriasis, etanercept can significantly improve skin clearance and quality of life[6]
  • In juvenile idiopathic arthritis, etanercept has shown to be effective in reducing joint inflammation and improving overall well-being in children[7]

Potential Side Effects

Like all medications, etanercept can cause side effects. Some of the most common side effects include:

  • Injection site reactions (redness, itching, or swelling at the injection site)
  • Upper respiratory infections
  • Headache
  • Nausea

More serious side effects, although rare, can include:

  • Serious infections
  • Allergic reactions
  • Blood disorders
  • Nervous system problems

It’s important to discuss potential side effects with your healthcare provider and report any unusual symptoms promptly[7].

Long-Term Use and Discontinuation

Etanercept is often used as a long-term treatment to manage chronic inflammatory conditions. However, some studies have investigated the possibility of discontinuing etanercept after achieving disease remission (a state of low disease activity or no symptoms). The success of discontinuation varies among patients and depends on factors such as the specific condition being treated and how long the patient has been in remission[10].

In some cases, patients may be able to stop etanercept treatment without experiencing a disease flare (return of symptoms). However, if symptoms do return, restarting etanercept is often effective in regaining control of the disease[10].

Monitoring During Treatment

While on etanercept, regular monitoring is essential to assess the treatment’s effectiveness and watch for potential side effects. This may include:

  • Regular blood tests to check for any changes in blood cell counts or liver function
  • Periodic assessments of disease activity using standardized measures such as the Disease Activity Score (DAS28) for rheumatoid arthritis or the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for ankylosing spondylitis[5]
  • Monitoring for signs of infection
  • In some cases, ultrasound examinations may be used to assess joint inflammation[8]

Your healthcare provider will determine the appropriate monitoring schedule based on your individual needs and response to treatment.

Aspect Details
Conditions Studied Ankylosing spondylitis, rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis
Key Efficacy Measures BASDAI, DAS28, PASI scores, ACR response criteria, radiographic progression
Safety Assessments Adverse events, injection site reactions, anti-drug antibody formation
Dosing Regimens 50 mg weekly or 25 mg twice weekly in most trials
Comparators Placebo, continued treatment vs. withdrawal
Special Populations Pediatric patients (juvenile idiopathic arthritis)
Long-term Outcomes Sustained remission, radiographic non-progression

Ongoing Clinical Trials on Etanercept

  • Study on Treatment Strategies for Children and Adolescents with Juvenile Idiopathic Arthritis Using Methotrexate and Drug Combination

    Recruiting

    3 1 1 1
    Investigated diseases:
    Norway
  • Study Comparing Step-up and Step-down Treatment Strategies with Methotrexate and Etanercept for Children with Juvenile Idiopathic Arthritis

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy
  • Study on the Effectiveness and Safety of Etanercept for Patients with SAPHO Syndrome

    Recruiting

    4 1 1 1
    Investigated diseases:
    Poland
  • Study on Baricitinib and Anti-TNF Drug Combination for Patients with Rheumatoid Arthritis

    Recruiting

    3 1 1
    Investigated diseases:
    France
  • Study on the Effectiveness of Etanercept and Methotrexate for Patients with Giant Cell Arteritis

    Recruiting

    2 1 1 1 1
    Investigated diseases:
    Poland
  • Study on Tildrakizumab and Etanercept for Children Aged 6 to 17 with Moderate to Severe Plaque Psoriasis

    Recruiting

    4 1 1
    Investigated drugs:
    Hungary Poland Slovakia Spain
  • Study on Sarilumab and Etanercept for Rheumatoid Arthritis in Patients Not Responding to csDMARD Therapy

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Italy The Netherlands Portugal Spain
  • Study on Reducing Immunosuppressive Drugs in Adults with Psoriatic Arthritis: Methotrexate Disodium, Abatacept, and Certolizumab Pegol

    Recruiting

    3 1 1 1
    Investigated diseases:
    Germany Italy
  • Study Comparing Methotrexate or Leflunomide with Targeted Therapy vs. Methotrexate or Leflunomide with Drug Combination for Rheumatoid Arthritis Patients

    Recruiting

    3 1 1 1
    Investigated diseases:
    France
  • Study on Early Drug Withdrawal in Children with Juvenile Idiopathic Arthritis Using Secukinumab and Drug Combination for Those in Clinical Remission

    Recruiting

    3 1 1 1
    Investigated diseases:
    Belgium Czechia Denmark Italy Lithuania Portugal +1

Glossary

  • BASDAI: Bath Ankylosing Spondylitis Disease Activity Index – A measure of disease activity in ankylosing spondylitis based on patient-reported symptoms.
  • DAS28: Disease Activity Score 28 – A measure of disease activity in rheumatoid arthritis based on examination of 28 joints.
  • PASI: Psoriasis Area and Severity Index – A tool used to measure the severity and extent of psoriasis.
  • Anti-drug antibodies (ADA): Antibodies produced by the body against a medication, which can reduce its effectiveness.
  • Biosimilar: A biologic medical product that is highly similar to an already approved biological medicine.
  • NSAID: Non-Steroidal Anti-Inflammatory Drug – A class of medications used to reduce pain and inflammation.
  • Remission: A state of disease where symptoms are minimal or absent.
  • Radiographic progression: Changes in joint damage visible on x-rays over time.

References

  1. https://clinicaltrials.gov/study/NCT01623752
  2. https://clinicaltrials.gov/study/NCT01793285
  3. https://clinicaltrials.gov/study/NCT01100034
  4. https://clinicaltrials.gov/study/NCT00245960
  5. https://clinicaltrials.gov/study/NCT02202850
  6. https://clinicaltrials.gov/study/NCT02486302
  7. https://clinicaltrials.gov/study/NCT01421069
  8. https://clinicaltrials.gov/study/NCT02202837
  9. https://clinicaltrials.gov/study/NCT02164214
  10. https://clinicaltrials.gov/study/NCT01287715